Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease

Fig. 2

The DNA methylation biomarker set detects difference in the disease burden after treatment of pancreatic adenocarcinoma. The boxplots show the mean DNA methylation signal per marker for 9 pairs of blood samples taken before the treatment and 4 weeks after the first cycle of treatment started. The y-axis is in a log2 scale. p = 3.9 × 10–3 by Wilcoxon signed rank test

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us